Content about Takeda Pharmaceutical Company

May 8, 2013
Takeda to acquire Colo. maker of vaccines for tropical diseases

Japanese drug maker Takeda Pharmaceutical Co. will buy Fort Collins, Colo.-based vaccine maker Inviragen for up to $250 million, the two companies said Wednesday.

December 17, 2012
Takeda to sell URL Pharma to Caraco Pharmaceutical Labs

Japanese drug maker Takeda Pharmaceutical Co. is selling its generics business to India-based Sun Pharmaceutical Industries, Takeda said.

October 2, 2012
Takeda, Lundbeck seek FDA nod for depression drug

Drug makers Takeda Pharmaceutical and H. Lundbeck have applied with the Food and Drug Administration for a new drug to treat depression in adults.

August 17, 2012
Ranbaxy launches authorized generic diabetes drug

Ranbaxy Labs has launched an authorized generic version of a diabetes drug made by Takeda Pharmaceutical, Ranbaxy said Friday.

August 17, 2012
Teva launches authorized generic Actos

Teva Pharmaceutical Industries announced the launch of an authorized generic of a Type 2 diabetes drug.

July 30, 2012
Takeda resubmits diabetes drug applications

Drug maker Takeda Pharmaceutical has resubmitted regulatory approval applications for two drugs designed to treat diabetes, the company said.

July 23, 2012
FDA approves blood cancer drug

The Food and Drug Administration has approved a new drug for treating multiple myeloma, the agency said Friday.

June 4, 2012
Takeda completes URL Pharma acquisition

Drug maker Takeda Pharmaceutical has finished its purchase of URL Pharma, the companies said Monday.

April 26, 2012
FDA declines to approve Takeda diabetes drug

The Food and Drug Administration declined to approve a drug made by Takeda Pharmaceutical, the drug maker said.

April 11, 2012
Takeda acquires URL Pharma

Takeda Pharmaceutical will acquire privately owned drug maker URL Pharma for $800 million, the companies said Wednesday.

March 6, 2012
Takeda unit starts trial of lymphoma drug

Takeda Pharmaceutical's cancer drug unit has started a late-stage clinical trial of a drug for treating a rare form of lymphoma, the company said.

February 8, 2012
Takeda launches Edarbyclor

Takeda Pharmaceutical has launched a drug for treating high blood pressure in adults, the company said.

November 28, 2011
Takeda files for approval of alogliptin-metformin combination tablet

A U.S. subsidiary of Takeda Pharmaceutical has filed for regulatory approval of a drug designed to treat Type 2 diabetes, the company said.

November 2, 2011
FDA approves update to Takeda cancer drug label

The Food and Drug Administration has approved changes to the labeling of a cancer drug made by Takeda Pharmaceuticals, the drug maker said.

October 19, 2011
Takeda launches late-stage trial program for Type 2 diabetes drug

Takeda Pharmaceuticals has started a late-stage clinical trial program for a drug to treat Type 2 diabetes, the drug maker said.

September 30, 2011
Takeda completes Nycomed acquisition

Drug maker Takeda has completed its acquisition of another drug maker.

August 5, 2011
Amylin, Takeda discontinue development of obesity drug

Amylin Pharmaceuticals and Takeda Pharmaceutical have halted development of a treatment for obesity in mid-stage clinical trials, the two companies said.

July 26, 2011
Takeda resubmits new drug applications for Type 2 diabetes treatments

Japanese drug maker Takeda Pharmaceutical is reapplying for approval of two drugs to treat Type 2 diabetes after the Food and Drug Administration turned down its last applications, the company said.

July 14, 2011
Takeda pulls two diabetes drugs off French market

OSAKA, Japan — Two diabetes drugs made by Takeda Pharmaceutical Co. have been pulled from the market in France due to evidence that their use may increase the risk of bladder cancer, Takeda said.

Takeda said its French subsidiary, Laboratoires Takeda, would withdraw Actos (pioglitazone) and Competact (pioglitazone and metformin). In addition, Takeda said it was cooperating with the European Medicines Agency in a pan-European of pioglitazone. Competact is marketed in the United States under the brand name Actoplus Met.

June 17, 2011
FDA updates ongoing safety review of Actos

The Food and Drug Administration on Thursday informed the public that continued use of a Type 2 diabetes treatment made by Takeda Pharmaceuticals for more than one year may be associated with an increased risk of bladder cancer.

May 12, 2011
Report: Takeda to acquire Nycomed in $12 billion deal

Japan-based Takeda Pharmaceutical may acquire Switzerland’s Nycomed for $12 billion, according to published reports.

April 15, 2011
Takeda's Edarbi enters market

Takeda Pharmaceutical has launched a new treatment for high blood pressure, the company said Friday.

April 5, 2011
Takeda tries to block Impax's launch of generic Dexilant

Generic drug maker Impax Labs is hoping to become the first to market a version of a gastroesophageal reflux disease treatment made by Takeda Pharmaceutical.

April 5, 2011
Takeda: Dexilant, Prevacid have less inhibiting effects on Plavix's efficacy than counterparts

Studies have indicated that proton-pump inhibitors, used for treating gastroesophageal reflux disease, reduce the efficacy of a popular blood-thinning drug, but Takeda Pharmaceuticals North America announced on Tuesday the results of a new study indicating that its own PPIs may have less of an effect.

March 25, 2011
Actos cuts Type 2 diabetes risk among majority of patients, study finds

A drug for Type 2 diabetes made by Takeda Pharmaceutical taken in the morning prevented the disease from developing in nearly three-quarters of patients who were at risk, according to a new study in the New England Journal of Medicine.

© 2013 Drug Store News. All Rights Reserved.